Abstract Library

#4592 Uncovering cell-state heterogeneity in large-cell panNEC indicates potentially targetable aberrant brain type neuronal de-differentiation

Introduction: Classification and treatment of high-grade pancreatic neuroendocrine carcinoma (panNEC), particularly those with large-cell morphology, present significant clinical challenges due to considerable inter- and intra-patient tumour heterogeneity.

Conference:

Presenting Author: Debnath O

Authors: Debnath O, Berger H, Detjen K, Kirchner P, Marinoni I,

Keywords: pancreatic neuroendocrine carcinoma, single cell, personalised medicine,

#4539 Single-nucleus profiling of the tumour microenvironment in SI-NET patients

Introduction: Small intestinal neuroendocrine tumours (SI-NETs) are frequently present as multiple synchronous primary tumours in the small bowel. They are thought to arise from enterochromaffin (EC) cells in the gut, which account for less than 1% of the intestinal epithelium. Previously reported lack of shared somatic driver alterations in SI-NETs suggests that other, non-genetic mechanisms are likely involved in their tumorigenesis.

Conference:

Presenting Author: Mäkinen N

Authors: Mäkinen N, Kasai Y, Kim G, Thirlwell C, Nakakura E,

Keywords: small intestinal NET, tumour microenvironment, single-nucleus sequencing,

#4258 Unanticipated heterogeneity in high-grade large-cell neuroendocrine carcinoma pinpoints cell sub-state specific therapeutic targets

Introduction: High-grade pancreatic neuroendocrine carcinoma (panNEC) pose challenges in terms of classification and treatment. While molecular genetics have made strides in deciphering significant inter-tumor heterogeneity, the extent of intra-tumoral heterogeneity and lineage plasticity remains unexplored.

Conference:

Presenting Author:

Authors: Debnath O, Detjen K, Berger H, Kirchner P, Marinoni I,

Keywords: PanNEC, Single cell RNAseq,

#3955 Development of clinically representative patient-derived organoid models for diverse G1/G2 gastroenteropancreatic neuroendocrine tumors

Introduction: While gastroenteropancreatic neuroendocrine tumors (GEP-NETs) grow slowly, they are incurable when reaching advanced stages. The characteristic slow growth of GEP-NETs results in the scarcity of clinically relevant models that has hindered our comprehension of GEP-NET biology and pathology, leading to limited progress in systemic therapies of GEP-NET treatment.

Conference:

Presenting Author:

Authors: Zuo X, Liu Y, Maxwelll J, Halperin D, Dasari A,

Keywords: gastroenteropancreatic neuroendocrine tumors, patient-derived organoids, Dox-controlled genetic modifications, characterization,

#3925 Telomerase-independence function of Dyskerin is therapeutic vulnerability in TP53 mutant pancreatic neuroendocrine tumors

Introduction: Pancreatic neuroendocrine tumors (PanNETs) utilize the recombination-mediated alternative lengthening of telomeres (ALT) mechanism, rather than telomerase, for the maintenance of telomeres.

Conference:

Presenting Author: Ji S

Authors: Ji S, Lou X, Zhou C, Xu X, Chen J,

Keywords: pancreatic neuroendocrine tumor, tp53 mutant, dyskerin, temozolomide,